<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
 <url>
  <loc>https://www.dottnet.it/articolo/32544171/sangue-e-plasma-nuova-alleanza-per-rafforzare-la-rete-delle-donazioni</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Sangue e plasma, nuova alleanza per rafforzare la rete delle donazioni</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544171-anteprimearticolidottnet-2026-10-26t092442230.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544172/melanoma-il-vaccino-personalizzato-a-mrna-riduce-del-42-il-rischio-di-recidiva</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Melanoma, il vaccino personalizzato a mRna riduce del 42% il rischio di recidiva</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544172-anteprimearticolidottnet-2026-10-26t094623508.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544176/tumori-forti-divari-in-europa-quasi-30-mila-casi-oltre-la-media</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Tumori, forti divari in Europa: quasi 30 mila casi oltre la media</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544176-anteprimearticolidottnet-2026-10-26t102402255.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544173/fondo-sanitario-gemmato-annuncia-nuovi-aumenti-nella-manovra</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Fondo sanitario, Gemmato annuncia nuovi aumenti nella manovra</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544173-spesasanitaria.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544174/igiene-e-medicina-preventiva-tornano-ad-attrarre-422-iscritti-nelle-scuole-di-specializzazione</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Igiene e Medicina preventiva tornano ad attrarre: 422 iscritti nelle Scuole di specializzazione</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544174-anteprimearticolidottnet-2026-10-26t100027994.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544155/melanoma-avanzato-hbi-8000-con-nivolumab-riduce-del-27-il-rischio-di-progressione</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Melanoma avanzato, HBI-8000 con nivolumab riduce del 27% il rischio di progressione</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544155-melanoma.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544177/microcitoma-polmonare-tarlatamab-con-durvalumab-riduce-del-58-il-rischio-di-morte</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Microcitoma polmonare, tarlatamab con durvalumab riduce del 58% il rischio di morte</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544177-businesswoman-using-digital-ribbon-cancer-interface-3d-rendering.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544178/farmacia-dei-servizi-vent-anni-di-evoluzione-dal-progetto-di-palazzo-marini-alla-sanita-di-prossimita</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Farmacia dei servizi, vent’anni di evoluzione: dal progetto di Palazzo Marini alla sanità di prossimità</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544178-farmacia-copia.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544179/farmacisti-vent-anni-di-trasformazione-dalla-dispensazione-all-assistenza-sul-territorio</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Farmacisti, vent’anni di trasformazione: dalla dispensazione all’assistenza sul territorio</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544179-anteprimearticolidottnet-2026-10-26t120915004.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544181/diabete-di-tipo-2-parere-positivo-del-chmp-per-icosema-una-sola-iniezione-settimanale</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Diabete di tipo 2, parere positivo del CHMP per IcoSema: una sola iniezione settimanale</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544181-top-view-diabetic-woman-checking-her-glucose-level.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544182/salute-genitale-maschile-microbiota-ed-epigenetica-nutrizionale</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Salute genitale maschile, microbiota ed epigenetica nutrizionale</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544182-uomo.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544183/roche-accelera-nel-2026-ricavi-in-crescita-e-nuove-evidenze-cliniche-tra-oncologia-neurologia-e-diagnostica</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Roche accelera nel 2026: ricavi in crescita e nuove evidenze cliniche tra oncologia, neurologia e diagnostica</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544183-16336.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544184/johnson-johnson-tumore-testa-collo-avanzato-amivantamab-in-combinazione-raggiunge-il-77-di-risposta</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Johnson &amp; Johnson, tumore testa-collo avanzato: amivantamab in combinazione raggiunge il 77% di risposta </news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544184-wavymed-07single-08.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544180/diabete-via-libera-ue-alla-nuova-terapia-settimanale-ora-accesso-rapido-anche-in-italia-</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Diabete, via libera UE alla nuova terapia settimanale: «ora accesso rapido anche in Italia»</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544180-anteprimearticolidottnet-2026-10-26t123455724.png</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544175/migranti-nei-cpr-su-lancet-l-allarme-sull-autonomia-dei-medici</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Migranti nei CPR, su Lancet l&#39;allarme sull&#39;autonomia dei medici</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544175-migranti.jpg</image:loc>
  </image:image>
 </url>
 <url>
  <loc>https://www.dottnet.it/articolo/32544185/oncologia-l-istituto-nazionale-dei-tumori-di-milano-coordina-jane-2-sette-reti-europee-per-migliorare-l-accesso-alle-cure</loc>
  <lastmod>2026-10-26T00:00:00.000Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Dottnet</news:name>
    <news:language>it</news:language>
   </news:publication>
   <news:title>Oncologia, l’Istituto Nazionale dei Tumori di Milano coordina JANE-2: sette reti europee per migliorare l’accesso alle cure</news:title>
   <news:publication_date>2026-10-26</news:publication_date>
  </news:news>
  <image:image>
   <image:loc>https://content.dottnet.it/content/articolo/32544185-cancer.jpg</image:loc>
  </image:image>
 </url>
</urlset>